RLY-2608
- Generic Name
- RLY-2608
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05216432
- Locations
- 🇺🇸
University of California-San Diego, San Diego, California, United States
🇺🇸Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States
🇺🇸Rutgers University, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath